Alnylam Pharmaceuticals recently presented comprehensive results from a clinical trial for its drug, vutrisiran, aimed at treating transthyretin…

This article 28% lower risk of death, 33% risk reduction—Could this be the new standard of care for a deadly heart condition? 🤔 appeared first on Guerilla Stock Trading.